Drug
Imlunestrant clinical trials
Also written LY3484356.
- studies test it
- 12
- open now
- 4
- in phase 3
- 2
- first study started
- 2021
Keep track of what changes. Save the Imlunestrant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
12 studies that test it; most in 2021 (4)
| Year | Studies |
|---|---|
| 2021 | 4 |
| 2022 | 4 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 4
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 3
Eli Lilly and Company (9) · Dana-Farber Cancer Institute (1) · Fudan University (1) · Jonsson Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
Abemaciclib (4) · Exemestane (1) · Fulvestrant (1) · Omeprazole (1) · Itraconazole (1) · Carbamazepine (1) · Selinexor (1)
Studies
Open first, then newest update. How each study uses Imlunestrant is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerRecruitingPhase 2Eli Lilly and CompanyNCT07287098Written as Imlunestrant
- Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialNot yet recruitingPhase 2Dana-Farber Cancer InstituteNCT07832227Written as Imlunestrant
- Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI TrialRecruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07191717Written as Imlunestrant
- Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07410559Written as Imlunestrant + abemaciclib
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT04975308Written as Imlunestrant
- A Study of LY3484356 in Chinese Participants With Advanced Breast CancerActive, not recruitingPhase 1Eli Lilly and CompanyNCT05509790Written as LY3484356
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT05514054Written as Imlunestrant
- A Study of LY3484356 in Healthy Female ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04840888Written as LY3484356
- A Study of [¹⁴C]-LY3484356 in Healthy Female ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04991766Written as [¹⁴C]-LY3484356
- A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver FunctionCompletedPhase 1Eli Lilly and CompanyNCT05440344Written as Imlunestrant
- A Study of Imlunestrant (LY3484356) in Healthy WomenCompletedPhase 1Eli Lilly and CompanyNCT05509816Written as Imlunestrant
- A Study of LY3484356 in Women With Breast Cancer Before Having SurgeryCompletedPhase 1Eli Lilly and CompanyNCT04647487Written as LY3484356
Given in every arm · 4 — Imlunestrant is usual care beside what is tested
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingPhase 1/2Eli Lilly and CompanyNCT05768139Written as Imlunestrant
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsActive, not recruitingPhase 1Eli Lilly and CompanyNCT05307705Written as Imlunestrant
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingPhase 1Eli Lilly and CompanyNCT04188548Written as LY3484356
- A Study of Imlunestrant (LY3484356) in Female Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05444556Written as Imlunestrant
Codes
What other systems call Imlunestrant · ClinicalTrials.gg INT001724
- MeSH (NLM) C000719756ImlunestrantConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 9CXQ3PF69UIMLUNESTRANTConfirmed FDA, NLM, Wikidata
- Wikidata Q123582076imlunestrantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174042ImlunestrantOne source FDA
- DrugBank DB19043One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719756 | Imlunestrant | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 9CXQ3PF69U | IMLUNESTRANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123582076 | imlunestrant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174042 | Imlunestrant | One source FDA |
| DrugBank | DB19043 | — | One source Wikidata |
Also registered as imlunestrant tosylate (UNII F7UDT90EW5).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.